Lantheus (NASDAQ:LNTH) Stock Rating Lowered by JonesTrading

Lantheus (NASDAQ:LNTH) was downgraded by equities research analysts at JonesTrading from a “buy” rating to a “hold” rating in a research report issued on Friday, MarketBeat Ratings reports.

LNTH has been the subject of a number of other reports. Mizuho upped their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Tuesday. Truist Financial upped their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. William Blair raised Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday. Finally, Citizens Jmp boosted their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Price Performance

Shares of LNTH opened at $74.91 on Friday. The stock has a 50 day simple moving average of $68.15 and a 200 day simple moving average of $60.19. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The firm has a market capitalization of $4.97 billion, a PE ratio of 22.23 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The business’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts predict that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. M&T Bank Corp acquired a new position in shares of Lantheus during the 4th quarter worth approximately $370,950,000. Farallon Capital Management LLC grew its stake in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Lantheus during the third quarter worth $65,654,000. Norges Bank bought a new stake in Lantheus during the fourth quarter worth $76,197,000. Finally, Polaris Capital Management LLC bought a new stake in Lantheus during the third quarter worth $32,687,000. 99.06% of the stock is currently owned by institutional investors.

More Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.